API Innovation Center

The API Innovation Center (APIIC) is looking forward to Breakthrough: A Health Innovation Symposium on April 16 during #STLTechWeek. Hosted by TechSTL, the event highlights the continued momentum around health and life sciences innovation in the St. Louis region. Dr. Chinh Ngo, Senior Process Chemist at APIIC, will present on the role of advanced manufacturing in reshoring generic pharmaceutical production. His session will explore how process innovation and emerging technologies can help address supply chain vulnerabilities and enable domestic production of critical medicines, right here in STL. Bringing together leaders across AI, health innovation and pharmaceutical manufacturing, the symposium will focus on applied technology, emerging research, commercialization pathways and the infrastructure required to scale innovation in health and life sciences. Register for this free event: https://lnkd.in/gZVpH9c7 #APIInnovationCenter #DrugSupplyChain #GenericMedicines #USManufacturing #HealthSecurity #SupplyChainResilience

“The real risk may not be today, but it raises a broader kind of bipartisan concern. The next event of disruption, if it’s more concentrated or is a critical part of our supply chain, what will happen?” asked Gerren McHam, vice president of government and external affairs at the API Innovation Center (APIIC). Recent coverage from The Hill reinforces a growing reality: the U.S. generic drug supply chain remains highly exposed to disruption. When production of pharmaceuticals and their critical ingredients is concentrated overseas, even a single disruption can have downstream effects on patient access—posing a clear national health security risk. This is the exact challenge APIIC was built to address. By advancing domestic production of active pharmaceutical ingredients and drug products, and by building a coordinated ecosystem across the supply chain, APIIC is working to reduce single points of failure and strengthen long-term supply chain resilience. Read the article here: https://lnkd.in/gWw_vDRA #APIInnovationCenter #DrugSupplyChain #GenericMedicines #USManufacturing #HealthSecurity #SupplyChainResilience

Member Spotlight: Kevin Webb with the API Innovation Center This month, we’re highlighting Kevin Webb, President and COO of the API Innovation Center (APIIC), a nonprofit corporation and public benefit organization dedicated to strengthening U.S. health security by reshoring active pharmaceutical ingredients (APIs) and key starting materials used in critical generic medicines. Kevin leads APIIC’s national efforts to modernize domestic pharmaceutical manufacturing to build a sustainable, market-competitive supply of U.S.-made APIs. APIIC research shows that 95% of the APIs used in the top ten medicines prescribed to seniors and veterans are manufactured overseas, underscoring the urgency of this work. APIIC joined EDSA because strengthening national health security and protecting vulnerable populations requires a shared strategy across manufacturers, health systems, distributors, and patient advocates. We’re proud to partner with leaders like Kevin who are helping secure reliable access to critical medicines. #EDSAMember #DrugShortages #HealthcareInnovation #MemberSpotlight

ASPR is teaming up with API Innovation Center (APIIC) to establish the first end-to-end domestic supply chain for metoprolol in decades. Under the new agreement, APIIC will also produce propofol, a surgical sedative. Metoprolol helps manage heart conditions and decreases lung inflammation for patients intubated in ICUs. When shortages occur, patients don’t just face inconvenience — they risk losing access to a medication that protects their lives and health. That’s why ASPR is partnering with the API Innovation Center (APIIC) to expand U.S. manufacturing capacity for the active pharmaceutical ingredient (API) propofol and the finished dosage form of metoprolol. This collaboration will modernize production capabilities across multiple consortium sites and reinforce the reliability of our supply chain. By integrating advanced manufacturing technologies, we’re enabling streamlined, uninterrupted production with the flexibility to rapidly scale in response to emergencies. That’s what we’re doing at ASPR. Onshoring essential medicines. Scaling Smarter. Strengthening domestic manufacturing. Creating jobs for American workers. Protecting American patients. https://lnkd.in/ePMwtEXb

The API Innovation Center (APIIC), today announced the expansion of its partnership with the U.S. Department of Health and Human Services (HHS)’ HHS Administration for Strategic Preparedness and Response (ASPR) to advance domestic manufacturing of propofol API and metoprolol and strengthen the resilience of the U.S. pharmaceutical supply chain. Over the past year, APIIC has been advancing a domestic manufacturing pathway for metoprolol API using modern process development techniques to enable efficient, scalable domestic production. This expanded program will enable the next phase of work— moving beyond API development to establish domestic production of finished metoprolol tablets and advance an end-to-end U.S. supply chain for this critical medicine. This marks the first use of Defense Production Act Title III authority to support U.S.-based manufacturing of a finished medicine. The collaboration reflects a broader national effort to strengthen end-to-end domestic supply chain resilience, reduce reliance on foreign sources and ensure reliable access to essential medicines through public-private partnerships. Read more: https://lnkd.in/enbg6ZQk #APIInnovationCenter #DrugSupplyChain #GenericMedicines #USManufacturing #HealthSecurity #SupplyChainResilience

For patients with asthma and other respiratory conditions, interruptions in access to essential bronchodilators can quickly become life-threatening. This is why EDSA continues advancing collaborative, data-informed solutions to help safeguard essential medicines. Because resiliency planning during stability protects patients during disruption. Learn more in the API Innovation Center’s 2025 Impact Report: https://lnkd.in/gxCgjEJ6 #DrugShortages #PatientAccess #Asthma

Missouri continues to gain momentum as a national hub for pharmaceutical innovation and manufacturing. The University of Missouri-Saint Louis's announcement of new federal funding to advance pharmaceutical R&D is another step forward in rebuilding domestic production of critical medicines—and strengthening the resilience of the U.S. supply chain. Proud to partner in this work and to see continued investment in the infrastructure, collaboration, and innovation needed to bring critical medicine production back to the United States. We’re grateful for the leadership of Congressman Wesley Bell in advancing investments that strengthen domestic pharmaceutical manufacturing and national health security. Read the full story from UMSL here: https://lnkd.in/gESjTRpK #API #DomesticManufacturing #Missouri #STL #SupplyChainResilience

The API Innovation Center has been named a finalist in the St. Louis Business Journal’s 2026 Best Places to Work Awards. This recognition reflects the people behind APIIC’s work. Every day, our team brings dedication, expertise and collaboration to advancing our mission to strengthen the U.S. pharmaceutical supply chain and support domestic manufacturing of critical medicines. From chemists to policy, data, partnerships and operations professionals, it is our people who drive the innovation and progress behind this mission. We’re proud to be part of the St. Louis innovation ecosystem and grateful for the team helping build solutions that strengthen the resilience of our nation’s pharmaceutical supply chain. Final rankings will be announced at the Best Places to Work event on May 14, with winners published in the May 15 edition of the St. Louis Business Journal. Read more: https://lnkd.in/dYuGdE7w #BestPlacesToWork #STLBusiness #PharmaManufacturing #SupplyChainResilience

Laura Bray and Angels for Change highlighted in the newly released white paper from the API Innovation Center, “Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain.” Bray emphasized a clear call to action for leaders across the healthcare ecosystem to work together to solve the drug shortage crisis: “This is not the patient’s job to solve at all… This is a supply chain failure.” The discussion underscored the urgent need for greater transparency and collaboration across the pharmaceutical supply chain. “Trust is the fuel to transparency. Transparency is the fuel to collaboration,” Bray said. The white paper also builds momentum around practical solutions—such as a “stoplight” early warning system being developed by the End Drug Shortages Alliance in along with Angels for Change to help identify supply changes before shortages reach patients. Patients and their care teams shouldn’t have to wonder whether their medicine will be there when they need it. That’s why we continue pushing forward to end drug shortages. Read the full white paper and join the conversation: APIIC White Paper: https://bit.ly/3P1adhZ #AngelsForChange #EndDrugShortagesNOW #ChangeMakers

Today, the API Innovation Center released its 2026 white paper, "From Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain," outlining a policy roadmap to secure the domestic generic drug supply chain. The paper builds on insights from panel discussions at APIIC’s 2025 plenary, where leaders from government, industry and academia examined the structural drivers of pharmaceutical supply chain fragility and strategies to rebuild domestic manufacturing capacity. At a time when more than 200 prescription medicines are currently in shortage nationwide, the report highlights recurring shortages not as isolated disruptions but as symptoms of a structurally fragile supply chain. To move towards measurable resilience, the white paper also introduces APIIC’s National Fragility Index, a proposed framework designed to quantify supply chain risk and identify where vulnerabilities are most concentrated. Read the announcement here: https://lnkd.in/gh49SSYU Read the full white paper here: https://lnkd.in/gs29xSGA #APIInnovationCenter #DrugSupplyChain #GenericMedicines #USManufacturing #HealthSecurity #SupplyChainResilience